Ask AI
ProCE Banner Activity

Targeting CDH6 in Platinum-Resistant Ovarian Cancer: Emerging ADCs, Biomarkers, and Sequencing

Podcast

In this podcast episode, experts discuss the scientific rationale and emerging clinical evidence for targeting CDH6 in platinum-resistant ovarian cancer, with a focus on CDH6-directed antibody–drug conjugates (ADCs) such as raludotatug deruxtecan and other investigational agents. The discussion examines CDH6 expression in ovarian tumors, the current limitations of biomarker testing and patient selection, and how ADC characteristics, including target expression, payload, linker properties, and drug-to-antibody ratio, may influence efficacy. Experts also review early clinical activity and key toxicities associated with CDH6-directed ADCs, including cytopenias, gastrointestinal adverse events, fatigue, and interstitial lung disease, and emphasize monitoring and supportive care considerations. The conversation further explores unresolved questions about ADC sequencing, potential cross-resistance between agents sharing topoisomerase I inhibitor payloads, changes in tumor biomarker expression over time, and the potential role of repeat biopsy in guiding treatment selection as additional targeted therapies become available.

Released: September 08, 2026

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational grants from Daiichi Sankyo, Inc and Merck Sharp & Dohme LLC.

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Target Audience

This activity is intended for oncologists, nurses, pharmacists, physician associates, and other global healthcare professionals who care for patients with ovarian cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Interpret the biologic rationale for targeting CDH6 in ovarian cancer, including overexpression and oncogenic role

  • Analyze the mechanism of action and structural design of next-generation CDH6-targeted antibody–drug conjugates

  • Appraise emerging clinical evidence regarding the efficacy and safety of CDH6-targeted antibody–drug conjugates in ovarian cancer

  • Formulate evidence-based strategies for biomarker-informed patient selection and sequencing of CDH6-directed ADCs in ovarian cancer

  • Apply evidence-based approaches for proactive multidisciplinary monitoring and management of adverse events associated with CDH6-directed ADCs

Financial Disclosures

Primary Author

Elizabeth Lee, MD: consultant/advisor/speaker: AstraZeneca, Genmab, GSK, OnCusp.

BJ Rimel, MD: advisor: AbbVie, Eisai, Merck, Tempus, Verastem.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.